Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Red light therapy shows promise for slowing Kids' nearsightedness

NCT ID NCT07375589

Disease control Sponsor: Shanghai Eye Disease Prevention and Treatment Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a low-intensity red light device could slow the worsening of nearsightedness (myopia) in children aged 8 to 12. Forty children participated, with some using the red light treatment for 3 months while others did not. The main goal was to see if the treatment reduced the lengthening of the eye, which is what causes myopia to get worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Apr 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 12 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 8-12 years old 2. Simple myopia: equivalent spherical lens ≤ -0.5D and \> -6.0D after any cycloplegia, astigmatism ≤ 2.5D, anisometropia ≤ 1.5D 3. The best corrected visual acuity in one eye is 0.8 and above 4. Normal fundus, or only leopard-shaped fundus 5. Sign informed consent and be able to participate in the study Exclusion Criteria: 1. Rule out hereditary myopia 2. The subject has other congenital eye diseases, such as congenital cataract, congenital glaucoma, etc 3. Presence of strabismus or other binocular vision abnormalities 4. refractive media opacity: corneal opacity, cataract or intraocular lens surgery 5. There are eye diseases that affect retinal function 6. Children who had used or were using orthokeratology, atropine and other myopia control measures could be enrolled after stopping treatment for three months 7. There are other systemic disease abnormalities 8. Other reasons that the research doctor considers unsuitable for inclusion in the project

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ametropia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ametropia Myopia

Contacts and locations

Locations

  • Shanghai Eye Disease Prevention & Treatment Center

    Shanghai, Shanghai Municipality, 200041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.